Last update 19 Nov 2026

Luspatercept-AAMT

Overview

Basic Info

Drug Type
Fc fusion protein
Synonyms
Luspatercept, ACE-536, BMS 986346
+ [7]
Action
inhibitors
Mechanism
ACVR2B inhibitors(Activin receptor type-2B inhibitors), GDF11 inhibitors(growth differentiation factor 11 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (08 Nov 2019),
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (Japan), Orphan Drug (South Korea), Paediatric investigation plan (European Union), Conditional marketing approval (China)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Non-transfusion dependent thalassaemia
European Union
20 Mar 2023
Non-transfusion dependent thalassaemia
Iceland
20 Mar 2023
Non-transfusion dependent thalassaemia
Liechtenstein
20 Mar 2023
Non-transfusion dependent thalassaemia
Norway
20 Mar 2023
Anemia
South Korea
09 May 2022
Anemia, Sideroblastic
European Union
25 Jun 2020
Anemia, Sideroblastic
Iceland
25 Jun 2020
Anemia, Sideroblastic
Liechtenstein
25 Jun 2020
Anemia, Sideroblastic
Norway
25 Jun 2020
Myelodysplastic Syndromes
European Union
25 Jun 2020
Myelodysplastic Syndromes
Iceland
25 Jun 2020
Myelodysplastic Syndromes
Liechtenstein
25 Jun 2020
Myelodysplastic Syndromes
Norway
25 Jun 2020
Transfusion dependent anaemia
European Union
25 Jun 2020
Transfusion dependent anaemia
Iceland
25 Jun 2020
Transfusion dependent anaemia
Liechtenstein
25 Jun 2020
Transfusion dependent anaemia
Norway
25 Jun 2020
Transfusion-dependent Beta Thalassemia
European Union
25 Jun 2020
Transfusion-dependent Beta Thalassemia
Iceland
25 Jun 2020
Transfusion-dependent Beta Thalassemia
Liechtenstein
25 Jun 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
MyelofibrosisPhase 3
China
23 Feb 2022
Polycythemia VeraPhase 3
China
23 Feb 2022
Thrombocythemia, EssentialPhase 3
China
23 Feb 2022
Post-polycythemia vera myelofibrosisPhase 3
United States
25 Feb 2021
Post-polycythemia vera myelofibrosisPhase 3
China
25 Feb 2021
Post-polycythemia vera myelofibrosisPhase 3
Japan
25 Feb 2021
Post-polycythemia vera myelofibrosisPhase 3
Argentina
25 Feb 2021
Post-polycythemia vera myelofibrosisPhase 3
Australia
25 Feb 2021
Post-polycythemia vera myelofibrosisPhase 3
Austria
25 Feb 2021
Post-polycythemia vera myelofibrosisPhase 3
Belgium
25 Feb 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
-
21
vjthzvjrql(jgbhmlnqps) = nsgdiidgza zylbvwmdvb (dkhetgwmho )
Positive
12 Dec 2026
Not Applicable
83
avqdysxnsm(pvkhwgfibl) = yyljrjjscc lohgexrupb (okfmuqioae )
Positive
12 Dec 2026
Phase 3
313
(BL TB <6 RBC U/12 wks)
bbioqbehgp(wdytpvtbva) = tnvdmxrmpv cslafivezx (zpmzqoyfba )
Positive
12 Dec 2026
Placebo
(BL TB <6 RBC U/12 wks)
bbioqbehgp(wdytpvtbva) = dxghikktri cslafivezx (zpmzqoyfba )
Not Applicable
146
tsqydmocqy(dczqwfptia) = pczimpamlu ojvcwgwqxg (sotacxbqpu, 56 - 79)
Positive
12 Dec 2026
(First-line)
tsqydmocqy(dczqwfptia) = mdhddwnhse ojvcwgwqxg (sotacxbqpu, 23 - 63)
Phase 3
Myelofibrosis
GDF11 | Hepcidin | serum EPO ...
217
eghqhsfeny(rnlkvcwksw) = xpevwfyxbb wsipqovaep (wntagixggk )
Positive
12 Dec 2026
JAK inhibitors
(Placebo)
eghqhsfeny(rnlkvcwksw) = cxdzayibpm wsipqovaep (wntagixggk )
Not Applicable
172
ESA as 1st line therapy
(SF3B1 MT)
mkivnkaive(lmvjbeuxur) = uogcugruvb waqadtbmqv (efhareitix )
Positive
12 Dec 2026
Luspatercept as 1st line therapy
(SF3B1 WT)
mkivnkaive(lmvjbeuxur) = byheaoqbzd waqadtbmqv (efhareitix )
Phase 2
28
ajlvgqmjnr(brpwwtfwex) = tricuurjbq sqdbnwqbnj (pisaxdyrad )
Positive
12 Dec 2026
Placebo
ajlvgqmjnr(brpwwtfwex) = vftiykqalq sqdbnwqbnj (pisaxdyrad )
Not Applicable
20
rrrkdajayq(hahmvgtrjo) = No drug-related adverse events occurred ksxzxnjgiq (uqwfmpelie )
Positive
12 Dec 2026
Not Applicable
100
kfakqhkmod(etrmdzpvst) = iutcqsmxqs udpzaolgkd (iudalgirxx )
Positive
12 Dec 2026
Phase 2
SF3B1 mutation
18
eanppozonq(plzfoqjglr) = AE cases having a prevalence of >15% included arterial hypertension (33.3%), peripheral oedema (27.8%), diarrhea (27.8%), arthralgia (22.2%), fatigue (22.2%), headache (22.2%), nausea (22.2%) and influenza like illness (16.7%). yqokpdsnul (tmfvhwskdz )
Positive
12 Dec 2026
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free